Imigene, Inc.

Imigene, Inc. is presently validating the Polarimetric Coagulation Assay (PCA) to provide high accuracy diagnostics for managing complex neuroinflammation and neurodegeneration cases related to COVID-19 and other causes using peripheral whole blood samples. The same test also supplies high accuracy screening for early stage cancers of the brain, breast, intestine, liver, lung, ovaries and pancreas.